Feature

Cell Technologies targeting joint disease with stem cell-based therapies

Closely held Cell Technologies is advancing regenerative medicine through proprietary autologous and allogeneic stem cell platforms designed to treat the pain and inflammation associated with osteoarthritis (OA) and...

April 7, 2026

Feature

PolarityBio changing the trajectory of wound care with autologous regenerative biologics

Closely held PolarityBio is developing investigational regenerative biologics for chronic wound healing, targeting some of the most refractory wounds in medicine. The company’s lead program and first entry into the...

March 17, 2026

Feature

Casp-Aid targeting neuronal neurodegeneration to restore cognition in Alzheimer disease

Closely held Casp-Aid is advancing a differentiated therapeutic strategy aimed at repairing damaged neurons responsible for cognitive impairment by targeting the root cause of neuronal damage in Alzheimer disease (AD)...

March 3, 2026

Feature

MediWound healing without surgery through a pineapple-derived enzymatic approach

MediWound (NASDAQ: MDWD) is advancing a proprietary enzymatic platform derived from bromelain, a proteolytic enzyme extracted from pineapple stems. The company’s non-surgical approach to necrotic tissue removal has...

February 24, 2026